With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5908-62-3,1,1-Dioxo-isothiazolidine,as a common compound, the synthetic route is as follows.
5908-62-3, To a stirred solution of 5-{9-fluoro-5-[(S)-(4-fluorophenyl)(oxan-4-yl)methyl]-6- methanesulfonyl-5H-pyrido[3,2-b]indol-3-yl}-4-(2H3)methyl-l-methyl-lH-l,2,3-triazole (24.0 mg, 0.0400 mmol) and isothiazolidine-l,l-dione (26.2 mg, 0.220 mmol) in NMP (0.25 mL) was added t-BuOK (19.4 mg, 0.170 mmol). This mixture was heated at 65 C for 2 h and cooled to room temperature. The mixture was then diluted with MeOH and purified via preparative LC/MS with the following conditions: Column: Waters XBridge Phenyl, 19 x 200 mm, 5-muiotaeta particles; Mobile Phase A: 5:95 ACN: water with 10 mM NH4OAc; Mobile Phase B: 95:5 ACN: water with 10 mM NH4OAc; Gradient: 15-70% B over 20 min, then a 5-min hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to give 2-{5-[(S)-(4- fluorophenyl)(oxan-4-yl)methyl]-6-methanesulfonyl-3-[4-(2H3)methyl-l -methyl-lH- l,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-9-yl} -l 6,2-thiazolidine-l,l-dione (11.6 mg, 40%). NMR (500MHz, DMSO-de) delta 8.73 (s, IH), 8.37 (d, J=8.5 Hz, IH), 7.90 (s, IH), 7.71-7.65 (m, 2H), 7.61 (d, J=8.4 Hz, IH), 7.16 (br t, J=8.7 Hz, 2H), 6.78 (br d, J=10.2 Hz, IH), 4.10 (br t, J=6.8 Hz, 2H), 3.88 (br d, J=10.7 Hz, IH), 3.83 (s, 3H), 3.64 (br d, J=8.7 Hz, IH), 3.57 (br t, J=7.5 Hz, IH), 3.47 (br s, 2H), 3.39 (br s, IH), 3.17 (br t, J=11.4 Hz, IH), 2.66-2.57 (m, 2H), 2.54 (s, 3H), 1.90 (br d, J=12.6 Hz, IH), 1.64 (br t, J=12.1 Hz, 2H), 0.42 (br d, J= 1.8 Hz, IH). LCMS: RT = 1.670 min; (ES): m/z (M+H)+ = 656.15. LCMS: Column: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7-muetaiota particles; Mobile Phase A: 5:95 ACN:water with 10 mM NH4OAC; Mobile Phase B: 95:5 ACN:water with 10 mM NH4OAc; Temperature: 50 C; Gradient: 0-100% B over 3 min, then a 0.75-min hold at 100% B; Flow: 1.11 mL/min. HPLC Purity at 220 nm: 98 %
As the paragraph descriping shows that 5908-62-3 is playing an increasingly important role.
Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; HAN, Wen-Ching; DEGNAN, Andrew P.; DESKUS, Jeffrey A.; GAVAI, Ashvinikumar V.; GILL, Patrice; SCHMITZ, William D.; STARRETT, John E., Jr.; (193 pag.)WO2016/183115; (2016); A1;,
Thiazolidine – Wikipedia
Thiazolidine – ScienceDirect.com